Kura Oncology begins dosing in Phase II trial of tipifarnib to treat lower risk MDS

US-based biopharmaceutical company Kura Oncology has dosed its first patient in a Phase II clinical trial of farnesyl transferase inhibitor, tipifarnib, to treat lower risk myelodysplastic syndromes (MDS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news